ReviewAllergy2017
Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.
Review in Allergy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03111628 (Role of Immunoglobulin E), which is not on this map. Cited by 108 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Role of Immunoglobulin E (IgE) Bearing Cells in Chronic Idiopathic Urticaria
Who cites it
108 citing papers in PubMed, 2 syntheses or guidelines pooled it, 277 citations in OpenAlex.
- Biologics and JAK inhibitors for atopic manifestations in inborn errors of immunity: a systematic review.Frontiers in allergy · 2026Pooled it
- Omalizumab for pediatric allergic asthma: evidence-based insights on efficacy and safety from a meta-analysis of randomized trials.Frontiers in pharmacology · 2026Pooled it
- Trial
- COVID-19 Immunologic Antiviral Therapy With Omalizumab (CIAO)-a Randomized Controlled Clinical Trial.Open forum infectious diseases · 2024Trial
- Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.American journal of respiratory and critical care medicine · 2020Trial
- Response of FcεRI-bearing leucocytes to omalizumab in chronic spontaneous urticaria.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2020Trial
- Chronic Spontaneous Urticaria in the Era of Targeted Therapy: From Pathogenic Mechanisms to Precision Medicine.Pharmaceutics · 2026Review
- Clinical and hematological parameters associated with omalizumab response in chronic spontaneous urticaria.Irish journal of medical science · 2026Article
- Article
- Research on chronic urticaria and angioedema: A bibliometric analysis of Web of Science Core Collection.Immunologic research · 2026Review
- Efficacy predictions for omalizumab treatment based on basophil CD203c expression in patients with allergic rhinitis by basophil activation test -- a real-life, pilot study.The World Allergy Organization journal · 2026Article
- Targeting Mast Cells in Chronic Spontaneous Urticaria.Current allergy and asthma reports · 2026Review
- Article
- The effect of omalizumab treatment on inflammatory parameters in urticarial diseases: a retrospective study.Postepy dermatologii i alergologii · 2026Article
- Evaluating antioxidant treatment approaches for eosinophilic chronic sinusitis.Frontiers in immunology · 2026Review
- Thyroid autoantibodies predict long-term treatment response in euthyroid chronic spontaneous urticaria: a retrospective cohort study with propensity score matching.Frontiers in medicine · 2026Article
- Challenges in Differentiating Chronic Inducible Urticaria from Chronic Spontaneous Urticaria.Journal of inflammation research · 2026Review
- Standardized pressure provocation as an objective clinical marker of omalizumab response in delayed pressure urticaria: an open-label, real-life, prospective cohort.Frontiers in immunology · 2026Article
- Chronic Spontaneous Urticaria with Biochemical C1 Inhibitor Deficiency: A Case Report of Suspected Overlap with Hereditary Angioedema.Clinical, cosmetic and investigational dermatology · 2026Article
- Omalizumab demonstrates efficacy and safety in Chinese children under 12 with chronic urticaria: a case series.Frontiers in pediatrics · 2026Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
The monoclonal anti-immunoglobulin E (IgE) antibody, omalizumab, was the first drug approved for use in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.